A new system that can use MRI scans to effectively measure myelin content in brain tissue may help assess the progression of multiple sclerosis (MS) and evaluate the effectiveness of treatments. The technique was described in “Quantitative magnetic resonance mapping of the myelin bilayer,” which…
News
Cionic’s Neural Sleeve, a leg-worn garment designed to boost strength and walking performance in people with conditions such as multiple sclerosis (MS), has won multiple awards in this year’s International Design Excellence Awards program. The event, organized by the Industrial Designers Society of America (IDSA), is touted as one of…
Diagnosing primary progressive multiple sclerosis (PPMS) can be challenging, with obstacles ranging from ruling out other disorders to differentiating between PPMS and other types of multiple sclerosis (MS). These difficulties were highlighted in the study, “Real-world challenges in the diagnosis of primary progressive multiple sclerosis,” published…
The presence of lesions, or regions of damage, in a brain circuit tied to memory in stroke patients also associate with memory problems in multiple sclerosis (MS), a study shows. Findings may help to determine which lesions are likely to cause memory issues in people with the neurodegenerative condition,…
The U.S. Food and Drug Administration (FDA) has approved Tyruko (natalizumab-sztn) as the first biosimilar of Tysabri to treat adults with relapsing forms of multiple sclerosis (MS). The decision also marks the first approval of any biosimilar for MS in the country, according to the regulatory agency.
Treatment with polysialic acid, a sugar molecule naturally made in the body, may be a promising approach to boost myelin repair in people with multiple sclerosis (MS), according to a new study in lab-grown brain samples. Findings show that the molecule increased myelin repair, or remyelination, in the cell…
A day of golfing is in store for those who want to support Johns Hopkins Hospital’s efforts on behalf of research for multiple sclerosis (MS) and to raise awareness about the progressive neurodegenerative disorder. The #spreadingORANGE event will aid the Johns Hopkins Multiple Sclerosis Center along with MS…
ASH41020, an investigational therapy from Ashvattha Therapeutics, significantly reduced disease severity and exhibited immunomodulatory properties in a mouse model of multiple sclerosis (MS), according to a recent presentation. Evidence indicated the therapy works by shifting the balance of immune cells called macrophages toward a less inflammatory and more…
Aubagio (teriflunomide) can significantly reduce the risk of developing multiple sclerosis (MS) among adults with signs of MS-like brain damage who don’t yet have any disease symptoms, according to findings from a clinical trial. The results were presented earlier this year at the American Academy of Neurology…
Children and adolescents with multiple sclerosis (MS) who receive high-efficacy disease-modifying therapies (DMTs) early on are significantly less likely to experience a relapse than those given a less efficacious drug, a real-world study found. While most patients on moderate-efficacy therapies eventually switched to a more effective one, a…
Noninvasive brain stimulation (NIBS) may offer promise for treating spasticity in multiple sclerosis (MS), but more work is needed to identify the best approach to use for patients, according to a new review study. The studies under review generally indicated that a type of brain stimulation called repetitive…
Older age and greater physical disability when starting a disease-modifying therapy (DMT) were linked to worse cognitive function for relapsing-remitting multiple sclerosis (RRMS) patients, but cognition remained relatively stable over the next several years, according to a Swedish study. Due to the high rates of DMT switches and…
Researchers have shed new light on the molecular mechanisms that help immune cells get into the brain to drive inflammation in multiple sclerosis (MS). Two proteins called MMP-9 and MMP-2 were found to break down some components of the barrier that keeps immune cells out of the brain, helping…
A global Phase 2 clinical trial investigating the oral therapy vidofludimus calcium (IMU-838) in people with progressive forms of multiple sclerosis (MS) has reached full enrollment, the treatment’s developer, Immunic Therapeutics, reports. Called CALLIPER (NCT05054140), the trial is assessing whether the neuroprotective effects of vidofludimus calcium seen in…
Levels of GFAP protein in the blood — a marker of damage to support cells in the brain — were associated with the enlargement of brain lesions and of fluid-filled brain cavities called ventricles in people with relapsing-remitting MS (RRMS) undergoing Tysabri (natalizumab) treatment, a study showed. While…
Atara Biotherapeutics now is planning to announce in November the one-year data from its EMBOLD Phase 1/2 study, which is testing the company’s experimental treatment ATA188 for progressive forms of multiple sclerosis (MS). The results, originally expected in October, will cover the trial’s primary endpoint of…
Disability progression in people with multiple sclerosis (MS) significantly reduces their quality of life, affects their ability to work, and represents a major socioeconomic cost, according to real-world data collected from a German MS registry. These results suggest that the use of disease-modifying therapies to slow MS progression…
People who experience a first attack of multiple sclerosis (MS)-like disease are less likely to experience long-term disability progression if they start  treatment within the first few months, a new study reports. “When it comes to MS treatment, the earlier the better,” Alvaro Cobo-Calvo, MD, PhD, co-author of the…
Pilates exercise with a relaxation technique improved walking abilities and self-awareness among people with multiple sclerosis (MS), according to a small study. The study, “Impact of Pilates suspension with self-awareness on gait and metacognition in multiple sclerosis: Randomized, single-blinded and parallel-group trial,” was published in…
Delivering an antibody against the Nogo-A protein to a specific region of the nose called the olfactory mucosa improved motor function and preserved myelin in the spinal cord of a mouse model of multiple sclerosis (MS), according to a recent study. This intranasal mode of delivery enabled significant concentrations…
A lab-engineered probiotic, composed of live bacteria that colonize the gut, was able to ease signs of disease in a mouse model of multiple sclerosis (MS), according to recent research. After discovering that a metabolite called lactate could activate immune signaling pathways that help to curb autoimmunity, scientists specifically…
By ordering a Teen Burger from an A&W in Canada tomorrow, customers can support MS Canada and people with multiple sclerosis (MS) in the country with one of the highest rates of the chronic neurodegenerative disease in the world. As part of the 15th annual “Burgers to…
A higher quality diet is associated with reductions in certain types of brain lesions in multiple sclerosis (MS), but no link was seen between a good diet and the risk of MS relapses or disability progression, a new study from Australia indicates. The study, “Higher…
The use of disease-modifying therapies (DMTs) does not seem to affect sleep quality or daytime sleepiness in people with multiple sclerosis (MS), an Australian study finds. However, patients with a belief that DMT use impacted their sleep tended to have poorer sleep quality and report that the medication…
People with multiple sclerosis (MS) with a rapid decline in walking abilities were more likely to be older when first examined, female, or Black, according to a large data study in the U.S. Other factors associated with worsening walking impairment over time included living with MS longer, having progressive…
Immune cells in the skull’s bone marrow show distinct molecular profiles from those of other bones throughout the body, and they may provide critical clues into how immune cells drive inflammation in neurological disorders like multiple sclerosis (MS) a study reports. “These findings carry profound implications, suggesting a far…
An antibody biomarker may help to distinguish people with a disease that resembles multiple sclerosis (MS), but may actually be its own clinical disorder, according to a new study. The biomarker was present in about 1% of MS patients and in 6% of those with a related demyelinating condition…
Researchers have developed a vaccine against the Epstein-Barr virus (EBV) — a leading environmental risk factor for multiple sclerosis (MS) — that induced durable immune responses in mice. If it’s moved to the clinic, the vaccine could help prevent infections that drive MS and certain cancers, according to…
Neuro Night, a philanthropic event set for October in Scottsdale, Arizona, is raising funds for the Barrow Neurological Institute and its mission of supporting the lifesaving care, medical education, and research for neurological diseases. The star-studded night of music, dancing, and fundraising, hosted by the Barrow Neurological Foundation,…
More daily physical activity, better physical condition, and lower disability were all associated with less fatigue for people with relapsing-remitting multiple sclerosis (RRMS), according to a clinical trial in Finland. “The findings are interesting and support previous studies very well,” Marko Luostarinen, a doctoral researcher at the University of…